A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (PODIUM-101)

Your email address will not be published. Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.